-
1 Comment
Elekta AB (publ) is currently in a long term uptrend where the price is trading 12.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Elekta AB (publ)'s total revenue sank by 2.1% to $4B since the same quarter in the previous year.
Its net income has increased by 4.5% to $322M since the same quarter in the previous year.
Finally, its free cash flow grew by 440.9% to $525M since the same quarter in the previous year.
Based on the above factors, Elekta AB (publ) gets an overall score of 4/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
Sector | Healthcare |
Industry | Medical Devices |
ISIN | SE0000163628 |
Market Cap | 2B |
---|---|
PE Ratio | 17.55 |
Target Price | None |
Dividend Yield | 5.2% |
Beta | 1.12 |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for EJXB.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025